UK – NICE pushes Doptelet for pre-surgery liver disease treatment

The National Institute for Health and Care Excellence (NICE) has published a new final draft guidance recommending Dova Pharmaceuticals’ Doptelet (avatrombopag) for thrombocytopenia - or low platelet count - in people with chronic liver disease needing surgery.

NICE says that the drug will be a “welcome innovative treatment”, as it can be administered at home, ultimately reducing the time spent in hospital. It also helps raise platelet levels for longer compared to platelet transfusions.

As it stands, the list price of the drug is £640.00 per five‑day treatment course for patients with 40,000 to below 50,000 platelets per microlitre of blood, and £960.00 for those with less than 40,000 platelets. Taken orally, the recommended dosage is 40mg or 60 mg once daily respectively…